Alnylam Pharmaceuticals, Inc. $ALNY Holdings Lowered by Westpac Banking Corp

Westpac Banking Corp decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 73.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,355 shares of the biopharmaceutical company’s stock after selling 3,718 shares during the quarter. Westpac Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $442,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after acquiring an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after acquiring an additional 185,783 shares during the period. Geode Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after acquiring an additional 75,936 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Alnylam Pharmaceuticals by 9.8% in the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company’s stock worth $475,353,000 after purchasing an additional 156,411 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares in the company, valued at $11,405,673.55. The trade was a 8.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This represents a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,200 shares of company stock valued at $25,709,053 in the last ninety days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $460.54 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock’s 50-day moving average is $458.91 and its two-hundred day moving average is $386.27. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market cap of $60.84 billion, a P/E ratio of -186.45 and a beta of 0.30.

Analysts Set New Price Targets

ALNY has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research note on Monday, October 13th. Truist Financial lifted their price target on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price on the stock. Finally, Chardan Capital upped their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday, August 1st. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.